An independent intelligence board aggregating credible research, preprints, clinical findings, biohacking experiments, and community discussions on therapeutic peptides, longevity science, and evidence-based anti-aging. Stories are scored for relevance, credibility, novelty, momentum, and practicality so the most important findings surface first.
A new study compared two prescription drugs used for weight loss: Mounjaro and Wegovy. Both are already prescribed for people trying to lose weight, but they work slightly differently. The study directly looked at how much weight people lost on one drug versus the other. Wegovy contains semaglutide, which copies a natural gut hormone that tells your brain you’re full and slows how fast your stomach empties. Mounjaro’s active ingredient is tirzepatide, which acts on two of those gut-brain receptors at once (it hits both GIP and GLP-1 receptors). In plain terms, both drugs make you feel less hungry and help you eat less, but tirzepatide is designed to give a stronger nudge by targeting two signals instead of one. The research compared people taking tirzepatide (Mounjaro) with those taking semaglutide (Wegovy) and measured weight loss. Depending on the trial details, studies like this typically report average percent weight loss over several months. From what’s reported, tirzepatide tended to produce larger average weight loss than semaglutide in the same time frame. It’s important to note whether the study was large, how long it ran, and whether participants had similar diets, exercise, or other health issues — those details affect how broadly we can apply the results. If the study was done in many people and over a long period, the findings are more reliable than a small or short study. For someone thinking about treatment, this matters because slightly different drugs can give different results and side-effect profiles. People struggling with obesity or medically driven weight concerns might talk with their doctor about whether one option could fit their situation better. For clinicians, the comparison helps guide which drug to prescribe first, especially when aiming for greater weight loss or when treating conditions like diabetes alongside excess weight. There are caveats. These drugs can cause side effects like nausea, diarrhea, or constipation, and not everyone responds the same way. Longer-term safety and what happens when people stop the drugs remain active questions. Cost and access are also practical issues; some medicines are approved for weight loss while others are not in every country, and insurance coverage varies. Finally, the strongest findings come from robust, peer-reviewed trials — if this comparison is preliminary or industry-funded, take the results cautiously. Bottom line: in head-to-head testing, tirzepatide (Mounjaro) has shown larger average weight loss than semaglutide (Wegovy), but individual results, side effects, cost, and long-term outcomes still need careful consideration with a doctor.
Source: Royal Australian College of General Practitioners (RACGP)